Author information
1Department of Diagnostic, Molecular, and Interventional Radiology, BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. bachir.taouli@mountsinai.org.
2Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.
3Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA.
4Department of Radiology, Institute for Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
5Department of Radiology, University of California San Diego, La Jolla, CA, USA.
6Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
7Global Medical and Clinical Affairs and Digital Development, Radiology, Bayer Pharmaceuticals, Berlin, Germany.
8Department of Diagnostic Radiology, Royal Marsden Hospital, Sutton, UK.
9Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
10Department of Radiology, Seoul National University Hospital and Seoul National University College of Medicine, Seoul, South Korea.
11Department of Radiology, Kobe University Graduate School of Medicine, Kobe, Japan.
12Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
13Department of Diagnostic and Interventional Radiology, Hannover Medical School, Hannover, Germany.
14Department of Radiology, West China Hospital, Sichuan University, Chengdu, People's Republic of China.
15Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
16Department of Radiology, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou; Liver Disease Hospital, Sun Yat-Sen University, Guangzhou, People's Republic of China.
17Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
18Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
19Université Paris Cité and Department of Radiology, Assistance-Publique Hôpitaux de Paris, APHP Nord, Hôpital Beaujon, Clichy, France.
Abstract
The 10th Global Forum for Liver Magnetic Resonance Imaging was held in October 2021. The themes of the presentations and discussions at this Forum are described in detail in the review by Taouli et al (2023). The focus of this second manuscript developed from the Forum is on multidisciplinary tumor board perspectives in hepatocellular carcinoma (HCC) management: how to approach early-, mid-, and late-stage management from the perspectives of a liver surgeon, an interventional radiologist, and an oncologist. The manuscript also includes a panel discussion by multidisciplinary experts on three selected cases that explore challenging aspects of HCC management. CLINICAL RELEVANCE STATEMENT: This review highlights the importance of a multidisciplinary team approach in liver cancer patients and includes the perspectives of a liver surgeon, an interventional radiologist, and an oncologist, including illustrative case studies. KEY POINTS: • A liver surgeon, interventional radiologist, and oncologist presented their perspectives on the treatment of early-, mid-, and late-stage HCC. • Different perspectives on HCC management between specialties emphasize the importance of multidisciplinary tumor boards. • A multidisciplinary faculty discussed challenging aspects of HCC management, as highlighted by three case studies.